Locus Biosciences Inc.
Morrisville, NC
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 523 Davis Dr #350, Morrisville, NC 27560, USA
- Website
- locus-bio.com
- Founded
- 2015
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $5,271,052 |
| FY2026 | $4,576,910 |
| FY2025 | $28,257,626 |
| FY2024 | $23,887,628 |
| FY2023 | $7,809,935 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $9,847,962 |
Contract awards
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Trustees Of Boston University | 75A50122C00028 | -$400,000 | |
| Trustees Of Boston University | 75A50122C00028 | $1,026,565 |
Similar vendors
About the company
Locus Biosciences Inc. is a clinical-stage biopharmaceutical company located in Morrisville, North Carolina, specializing in developing innovative antibacterial therapies using engineered bacteriophages. Registered in SAM.gov since October 28, 2015, the company is a for-profit corporate entity focused on creating advanced therapeutic solutions targeting serious bacterial infections. Their primary research and development efforts concentrate on developing engineered viruses capable of precisely targeting and eliminating specific bacterial strains, with a particular emphasis on addressing urinary tract infections caused by drug-resistant bacteria.
Through federal contract awards, Locus Biosciences Inc. has secured a significant $3,318,955 cost-plus-fixed-fee definitive contract from the National Institute of Allergy and Infectious Diseases (NIAID). This contract, awarded on September 24, 2025, aims to advance a novel therapeutic to a first-in-human clinical study, with a completion date of February 7, 2029. The company has also engaged in sub-contract work with Trustees of Boston University, specifically focusing on optimizing bacteriophage cocktails targeting K. pneumoniae and developing strategies to address complicated urinary infections. These contract awards are not set-aside and demonstrate the company's commitment to developing innovative bacterial treatment approaches that can potentially address infections resistant to traditional antibiotic treatments.
In the realm of federal grant awards, Locus Biosciences Inc. has collaborated with Trustees of Boston University on sub-grant projects related to their bacteriophage research. The October 27, 2020 grant award supported the creation of a crPhage cocktail targeting K. pneumoniae, with options for early clinical development. This grant work aligns closely with the company's overarching research goal of developing a comprehensive arsenal of bacteriophage cocktails targeting multiple bacterial species. By focusing on E. coli and K. pneumoniae, Locus Biosciences aims to create therapeutic solutions that can potentially treat over 90% of urinary tract infections, regardless of the underlying drug resistance within the bacterial species.
SBA capabilities narrative
LOCUS BIOSCIENCES, INC. is a Small Business located in Morrisville, NC. LOCUS BIOSCIENCES, INC. delivers consistent and quality services to its customers with the highest level of integrity and great attention to people, products, and service. They are passionate about their business and go to extraordinary lengths to satisfy their customers. LOCUS BIOSCIENCES, INC.'s vision is to create and strengthen relationships with their customers by providing exceptional service and consistently demonstrating their quality services. LOCUS BIOSCIENCES, INC. and its employees take great pride in their work and in delighting their customers.
Quick answers
Is Locus Biosciences Inc. registered in SAM.gov?
Yes. Locus Biosciences Inc.'s SAM.gov registration is active through January 2, 2027.
What is Locus Biosciences Inc.'s CAGE code?
Locus Biosciences Inc.'s CAGE code is 7H2T2, and its Unique Entity ID (UEI) is CJKVLKZGX6F3.
How much has Locus Biosciences Inc. received in federal contracts?
Federal contracts obligated $28,257,626 to Locus Biosciences Inc. in fiscal year 2025 and $69,803,151 in fiscal years 2023 through 2027.
How does Locus Biosciences Inc. rank among federal contractors?
Locus Biosciences Inc. ranked #7 in PSC AN13, #15 in NAICS 541714 and #22 in PSC AN in FY2025.
What is Locus Biosciences Inc.'s most recent federal award?
Locus Biosciences Inc.'s most recent federal contract award is Advance a novel therapeutic to a first-in-human clinical study (75N93025C00035), from National Institute of Allergy and Infectious Diseases (NIH), on September 24, 2025.
On GovTribe
See Locus Biosciences Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors